No definition available.
Progressive supranuclear ophthalmoplegia (Steele-Richardson-Olszewski)
G6_PROGRESSIVE_SUPRANUCLEAR_OPHTHALMOPLEGIA
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
194 |
4. Check minimum number of eventsNone |
194 |
5. Include endpointsNone |
194 |
6. Filter based on genotype QC (FinnGen only) |
189 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Similar endpoints
↥List of similar endpoints to
Progressive supranuclear ophthalmoplegia (Steele-Richardson-Olszewski)
based on the number of shared cases.
Similar with more cases:
- Other degenerative diseases of the basal ganglia
- Extrapyramidal and movement disorders
- Neurological diseases
- Neurological diseases, wide definition
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded (different definition than used in FinnGen).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 189 | 66 | 123 |
| Unadjusted period prevalence (%) | 0.04 | 0.02 | 0.06 |
| Median age at first event (years) | 75.25 | 75.14 | 75.31 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 194
- Matched controls
- 1940
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G23.1
ICD-10 Finland
Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]
+∞
277.5
193
*
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
153.6
264.7
153
46
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
72.7
176.7
105
31
G20
ICD-10 Finland
Parkinson disease
62.9
161.0
98
31
N87
ICPC
Parkinsonism
81.2
130.6
72
14
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
60.9
37.5
43
9
L28
ICPC
Limited function/disability (L)
5.3
29.3
90
271
G23.9
ICD-10 Finland
Degenerative disease of basal ganglia, unspecified
113.0
27.5
29
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
6.6
23.6
44
83
S01.0
ICD-10 Finland
Open wound of scalp
6.2
23.2
46
92
N06DA03
ATC
rivastigmine; oral, transdermal
7.1
23.2
39
66
R4130
NOMESCO Finland
Speech therapy
10.0
22.1
27
31
D21
ICPC
Swallowing problem
29.5
21.1
28
11
A28
ICPC
Limited function/disability NOS
4.1
20.2
87
324
SPAT1229
SPAT
Assessment of need for aid
5.4
19.2
44
100
N04BC04
ATC
ropinirole; oral
43.1
19.0
23
6
G04BD12
ATC
mirabegron; oral
4.4
18.9
61
183
N99
ICPC
Neurological disease other
41.0
18.0
22
6
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.8
18.0
84
326
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
3.6
17.3
108
503
R13
ICD-10 Finland
Dysphagia
5.1
17.2
41
96
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
4.2
15.2
48
140
R5110, ,
SPAT
5.5
15.1
32
67
SPAT1216
SPAT
Assessment of functional ability
3.6
14.8
66
244
N06AX11
ATC
mirtazapine; oral
3.2
14.2
94
441
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
81.0
13.8
15
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.6
13.7
58
206
N19
ICPC
Speech disorder
28.1
13.6
18
7
N05AH04
ATC
quetiapine; oral
3.8
13.6
51
167
AA1AD
NOMESCO Finland
CT of head and brain
3.1
13.4
94
452
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
4.1
12.8
40
115
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
12.9
12.7
22
19
AA5EN
NOMESCO Finland
Brain reseptor or transprot protein distribution isotope imaging
138.6
12.6
13
*
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
138.6
12.6
13
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.5
11.7
31
78
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.2
11.5
58
228
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
18.5
11.4
17
10
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.3
11.3
32
85
JDB10
NOMESCO Finland
Percutaneous gastrostomy
15.1
11.2
18
13
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
9.8
11.1
22
25
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
4.2
11.1
33
91
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
10.9
88
446
SPAT1245
SPAT
Provision of support and information to patient’s family members
4.8
10.9
26
60
U04
ICPC
Incontinence urine
4.7
10.8
27
65
R53
ICD-10 Finland
Malaise and fatigue
2.8
10.5
76
363
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
25.0
10.4
14
6
SPAT1234
SPAT
Support of social functional capacity
4.9
10.3
24
54
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
10.0
10.3
20
22
N04BD01
ATC
selegiline; oral
14.4
9.9
16
12
SPAT1215
SPAT
Assessment of need for medical rehabilitation
5.7
9.9
19
36
SPAT1231
SPAT
Assessment of adjustments needed in living environment
9.9
9.8
19
21
A04
ICPC
Weakness/tiredness general
3.1
9.8
48
184
A06AD11
ATC
lactulose; oral
2.9
9.7
56
236
N04BC05
ATC
pramipexole; oral
3.7
9.2
32
98
R47.1
ICD-10 Finland
Dysarthria and anarthria
13.4
9.0
15
12
N28
ICPC
Limited function/disability (N)
11.5
9.0
16
15
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
10.8
8.7
16
16
N29
ICPC
Neurological sympt/complt other
17.3
8.7
13
8
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.7
8.3
53
234
N03AE01
ATC
clonazepam; systemic
4.4
8.0
21
52
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.0
7.7
23
63
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.9
7.7
24
68
N06AB10
ATC
escitalopram; oral
2.9
7.5
41
165
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.3
7.5
81
455
P20
ICPC
Memory disturbance
2.5
7.3
56
268
W19
ICD-10 Finland
Unspecified fall
3.1
7.2
34
126
XA800
NOMESCO Finland
Neuropsychological investigation
7.2
7.0
16
24
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
7.6
6.8
15
21
R25.1
ICD-10 Finland
Tremor, unspecified
6.9
6.8
16
25
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.3
6.6
26
86
N30.0
ICD-10 Finland
Acute cystitis
2.8
6.6
37
151
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.5
6.5
23
71
R4130, ,
SPAT
72.1
6.5
7
*
XF606
NOMESCO Finland
Ortostatic test
27.7
6.3
8
*
S00.0
ICD-10 Finland
Superficial injury of scalp
7.1
6.2
14
21
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
34
122
3.17
7.64
1.9
1.8
—
—
—
0
0
13
15
9.20
6.67
1.0
1.0
625.50
429.57
ng/l
—
8
7
13
15
9.20
6.67
1.0
1.0
27.29
44.55
ng/l
—
7
6
75
428
2.23
6.48
1.9
1.7
1218.96
1167.61
nmol/l
0.12
51
322
91
574
2.10
5.98
2.7
2.1
284.62
385.70
u/l
0.25
84
537
59
331
2.12
5.15
2.2
1.9
—
—
—
0
0
44
227
2.21
4.70
2.1
1.8
—
—
—
0
0
43
227
2.15
4.32
2.1
1.9
—
—
—
0
0
108
795
1.81
3.97
2.2
2.1
93.12
92.25
pmol/l
0.07
57
428
113
860
1.75
3.56
4.7
6.2
1.22
1.21
mmol/l
0.74
101
779
29
146
2.16
3.26
1.2
1.5
—
—
—
0
0
8
15
5.51
3.22
2.5
2.1
—
—
—
0
0
119
936
1.70
3.18
5.9
6.8
1.22
1.21
mmol/l
0.85
97
780
15
56
2.82
3.14
1.2
1.2
—
—
—
0
0
91
670
1.67
3.09
3.1
2.2
—
—
—
0
0
105
810
1.65
2.93
4.1
4.3
35.13
34.45
g/l
0.55
96
763
25
124
2.17
2.92
1.4
1.3
—
—
—
0
0
29
157
2.00
2.70
1.9
2.5
26.70
34.94
u/l
0.89
23
127
6
11
5.59
2.56
1.0
1.0
—
—
—
0
0
16
70
2.40
2.49
1.7
1.7
—
—
—
0
0
23
121
2.02
2.32
2.3
3.9
3.00
2.16
mmol/l
0.37
11
93
81
614
1.55
2.27
2.0
3.3
2.34
2.35
mmol/l
0.21
64
534
101
804
1.53
2.26
5.3
4.4
0.00
0.00
estimate
-0.00
18
175
41
601
0.60
2.25
3.7
3.9
2.22
10.90
mg/mmol
3.80
25
387
7
20
3.59
2.07
1.4
1.2
—
—
—
0
0
6
15
4.09
2.05
1.0
1.0
—
—
—
0
0
6
15
4.09
2.05
1.0
1.0
—
—
—
0
0
124
1048
1.51
1.99
4.8
5.1
6.50
6.94
mmol/l
2.60
113
993
16
78
2.15
1.97
1.8
1.9
—
—
—
0
0
83
652
1.48
1.89
2.0
2.2
80.47
77.89
nmol/l
0.31
64
562
100
817
1.46
1.85
5.3
4.4
0.00
0.00
estimate
-0.00
17
154
99
808
1.46
1.84
6.8
5.8
0.00
0.00
estimate
-0.00
14
159
59
436
1.51
1.80
1.6
1.9
470.74
16193614.61
pmol/l
0.50
46
352
168
1537
1.69
1.72
22.5
18.5
33.23
26.77
mg/l
1.66
153
1275
5
13
3.92
1.72
1.0
1.4
—
—
—
0
0
5
13
3.92
1.72
1.0
1.4
—
—
—
0
0
130
1127
1.47
1.70
3.6
3.8
15.82
15.16
pmol/l
1.98
110
981
11
49
2.32
1.67
1.0
1.5
—
—
—
0
0
45
321
1.52
1.60
3.7
2.9
0.72
1.11
e6/l
0.62
26
192
69
540
1.43
1.55
3.6
3.4
0.23
0.47
e6/l
1.73
52
419
6
21
2.91
1.51
2.5
2.1
—
—
—
0
0
6
24
2.55
1.31
1.0
1.2
—
—
—
0
0
15
85
1.83
1.27
1.6
1.9
2.60
5.67
ug/l
—
9
76
144
1310
1.39
1.17
5.9
8.0
76.22
80.67
u/l
0.60
128
1225
0
35
0.00
1.16
0.0
1.7
—
—
—
0
0
0
35
0.00
1.16
0.0
1.7
—
—
—
0
0
5
20
2.54
1.16
1.2
1.5
—
—
—
0
0
41
307
1.43
1.15
3.9
3.2
2.25
1.81
e6/l
0.15
22
181
7
31
2.30
1.11
1.0
1.5
—
—
—
0
0
7
32
2.23
1.09
1.0
1.5
—
—
—
0
0
7
32
2.23
1.09
1.0
1.5
—
—
—
0
0
7
32
2.23
1.09
1.0
1.5
—
—
—
0
0
7
32
2.23
1.09
1.0
1.5
—
—
—
0
0
7
33
2.16
1.06
1.0
1.5
—
—
—
0
0
5
22
2.31
1.04
1.0
1.2
—
—
—
0
0
133
1206
1.33
1.03
3.9
4.4
10.67
15.02
mm/h
3.78
117
1085
154
1428
1.38
1.02
4.7
4.7
1.83
2.06
mu/l
1.65
133
1240
80
680
1.30
0.99
3.4
3.5
—
—
—
0
0
61
503
1.31
0.94
1.6
1.6
16.27
20.35
nmol/l
1.88
55
414
10
168
0.57
0.91
3.8
6.5
10.43
11.73
mmol/l
—
10
159
139
1490
0.76
0.89
5.9
7.1
39.98
41.71
mmol/mol
1.76
124
1350
37
465
0.75
0.83
2.1
3.0
13582.79
7213.41
umol/l
0.19
29
391
89
782
1.26
0.81
4.7
4.5
47.84
45.73
ng/l
0.04
71
622
141
1503
0.77
0.81
4.1
5.0
4.24
4.33
mmol/l
0.44
123
1341
39
309
1.33
0.79
1.5
3.2
0.82
0.82
mmol/l
0.04
34
291
59
499
1.26
0.74
2.4
2.0
2.87
3.25
mg/l
0.87
41
428
141
1492
0.80
0.66
4.0
5.0
1.41
1.42
mmol/l
0.08
121
1316
135
1435
0.81
0.66
3.7
4.5
1.20
1.25
mmol/l
0.42
113
1257
97
878
1.21
0.63
2.9
3.2
60.94
58.41
u/l
0.05
82
797
106
969
1.21
0.62
22.3
17.8
1.28
1.39
inr
0.39
23
274
0
20
0.00
0.60
0.0
1.1
—
20.80
—
0
5
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
2.8
—
—
—
0
0
0
22
0.00
0.59
0.0
1.5
—
—
—
0
0
0
22
0.00
0.59
0.0
1.5
—
—
—
0
0
44
369
1.25
0.59
2.6
3.3
2.42
2.46
mmol/l
1.50
37
323
0
23
0.00
0.58
0.0
1.8
—
—
—
0
0
0
23
0.00
0.58
0.0
1.8
—
—
—
0
0
0
23
0.00
0.58
0.0
1.8
—
—
—
0
0
11
160
0.67
0.58
3.8
3.2
5.57
4.37
kpa
0.69
11
151
44
376
1.22
0.50
4.3
3.8
59.47
293.19
ng/l
1.63
38
327
34
283
1.24
0.49
1.4
1.2
0.77
0.90
u/ml
—
7
68
148
1543
0.83
0.48
4.7
5.8
2.35
2.50
mmol/l
1.36
128
1361
19
147
1.32
0.47
2.0
3.9
53.93
89.88
ng/l
3.86
14
130
28
230
1.25
0.46
8.9
8.2
—
—
—
0
0
147
1529
0.84
0.43
4.6
5.5
5.98
6.20
mmol/l
1.84
125
1351
171
1660
1.25
0.42
30.2
26.8
237.16
233.49
e9/l
0.31
166
1612
171
1660
1.25
0.42
30.2
26.8
4.36
4.41
e12/l
0.81
165
1602
171
1660
1.25
0.42
30.2
27.0
39.19
39.45
%
0.23
156
1531
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
15
192
0.76
0.40
3.5
4.1
2.80
1.83
mmol/l
0.55
15
148
15
192
0.76
0.40
3.5
4.1
6.24
5.73
kpa
0.82
15
184
19
152
1.28
0.38
1.8
1.8
456.00
378.19
nmol/l
1.25
13
139
9
70
1.30
0.37
1.7
3.2
—
—
—
0
0
26
218
1.22
0.36
6.3
3.8
—
—
—
0
0
6
44
1.38
0.34
1.2
1.5
—
—
—
0
0
6
44
1.38
0.34
1.2
1.5
—
—
—
0
0
7
99
0.70
0.31
3.1
2.9
1.04
1.08
%
—
7
99
159
1630
0.86
0.28
9.6
11.9
22.89
24.66
u/l
0.47
151
1556
61
564
1.12
0.27
2.6
2.3
55.30
63.90
u/l
0.49
53
517
13
105
1.26
0.25
1.4
1.3
—
—
—
0
0
67
626
1.11
0.24
6.4
4.7
—
—
—
0
0
5
37
1.36
0.23
1.4
1.5
—
—
—
0
0
37
335
1.13
0.23
1.5
2.3
10.34
12.11
umol/l
0.84
30
304
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
309.60
—
0
5
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
143
1467
0.90
0.21
20.2
17.8
77.50
71.43
ml/min/173m2
4.03
120
1217
0
12
0.00
0.21
0.0
1.9
—
—
—
0
0
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
4.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
6
52
1.16
0.19
3.2
1.5
—
—
—
0
0
19
215
0.87
0.17
1.4
1.3
2.13
21.90
u/ml
—
7
74
11
92
1.21
0.16
5.9
2.5
—
—
—
0
0
21
230
0.90
0.12
3.0
4.8
2.48
61.02
ug/l
1.10
16
201
41
433
0.93
0.11
2.1
2.4
—
—
—
0
0
29
270
1.09
0.11
5.2
6.6
103.97
103.96
mmol/l
0.00
29
270
82
795
1.05
0.10
2.4
2.7
—
—
—
0
0
48
459
1.06
0.10
7.1
4.7
0.00
0.00
estimate
-0.00
16
157
5
48
1.04
0.09
2.0
1.4
—
—
—
0
0
6
54
1.11
0.09
1.2
1.2
—
—
—
0
0
66
679
0.96
0.07
2.9
3.4
844.50
1583.45
ng/l
2.19
56
588
90
919
0.96
0.07
5.1
9.9
4.39
4.40
e9/l
0.01
75
795
38
364
1.05
0.07
1.4
1.7
1.28
1.65
mg/l
0.40
25
294
128
1298
0.96
0.07
24.0
21.9
15.08
15.56
%
0.41
128
1277
88
862
1.04
0.06
4.9
5.7
2.60
3.47
ug/l
0.71
74
747
31
297
1.05
0.05
1.6
2.4
19.39
21.65
%
0.40
21
254
66
646
1.03
0.04
2.3
2.7
148.31
170.75
ug/l
0.35
55
575
12
112
1.08
0.03
3.0
7.4
25.14
24.83
mmol/l
0.08
12
112
18
172
1.05
0.02
5.3
7.1
1.13
1.36
mmol/l
1.22
18
166
51
519
0.98
0.02
2.4
2.9
32.43
35.00
u/l
0.21
44
490
24
233
1.03
0.01
3.7
5.2
34.94
32.78
%
0.52
17
145
93
937
0.99
0.01
4.6
6.6
11.41
12.37
umol/l
0.64
84
881
18
186
0.96
0.00
2.1
2.6
8.29
8.37
ug/l
0.01
12
164
15
149
1.01
0.00
1.3
1.2
—
—
—
0
0
49
488
1.01
0.00
2.9
3.2
0.84
0.86
ug/l
0.03
37
340
5
57
0.87
0.00
1.0
1.1
—
—
—
0
0
5
50
1.00
0.00
1.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
5.5
—
226.00
—
0
8
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
948.67
—
0
6
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
93.50
—
0
6
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
68
680
1.00
-0.00
5.0
4.8
21.18
21.55
%
0.09
40
352
0
8
0.00
-0.00
0.0
1.8
—
30.40
—
0
8
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
52
0.96
-0.00
2.2
1.3
—
—
—
0
0
5
49
1.02
-0.00
1.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.4
—
74.67
—
0
9
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded (different definition than used in FinnGen).
Relationships between endpoints
↥Index endpoint: G6_PROGRESSIVE_SUPRANUCLEAR_OPHTHALMOPLEGIA – Progressive supranuclear ophthalmoplegia (Steele-Richardson-Olszewski)
GWS hits: -
This endpoint is excluded (different definition than used in FinnGen).